Inhibikase Therapeutics (IKT) Revenue Growth (1y) (2021 - 2023)
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Revenue Growth (1y) (2021 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 12.45% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 16.73% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 59.71% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 2.11% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 29.63% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 66.86% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 16.50% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 296.11% |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -100.00% |
| Sep 30, 2023 | 991.33% |
| Jun 30, 2023 | 1,676.71% |
| Mar 31, 2023 | 40.17% |
| Dec 31, 2022 | 3,169.86% |
| Sep 30, 2022 | -97.78% |
| Jun 30, 2022 | -99.52% |
| Mar 31, 2022 | -96.73% |
| Dec 31, 2021 | -98.86% |
| Sep 30, 2021 | 771.71% |
| Jun 30, 2021 | 520.73% |
| Mar 31, 2021 | 419.66% |